- Home
- RMCO vs NXTC Comparison
RMCO vs NXTC Comparison
Compare RMCO & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- NXTC
- Stock Information
- Founded
- RMCO 2021
- NXTC 2015
- Country
- RMCO United States
- NXTC United States
- Employees
- RMCO N/A
- NXTC N/A
- Industry
- RMCO Multi-Sector Companies
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- NXTC Health Care
- Exchange
- RMCO Nasdaq
- NXTC Nasdaq
- Market Cap
- RMCO 14.9M
- NXTC 13.9M
- IPO Year
- RMCO N/A
- NXTC 2019
- Fundamental
- Price
- RMCO $1.65
- NXTC $4.80
- Analyst Decision
- RMCO
- NXTC Strong Buy
- Analyst Count
- RMCO 0
- NXTC 2
- Target Price
- RMCO N/A
- NXTC $25.50
- AVG Volume (30 Days)
- RMCO 66.4K
- NXTC 325.3K
- Earning Date
- RMCO 08-11-2025
- NXTC 08-07-2025
- Dividend Yield
- RMCO 0.31%
- NXTC N/A
- EPS Growth
- RMCO N/A
- NXTC N/A
- EPS
- RMCO N/A
- NXTC N/A
- Revenue
- RMCO $2,641,171.00
- NXTC N/A
- Revenue This Year
- RMCO N/A
- NXTC N/A
- Revenue Next Year
- RMCO N/A
- NXTC N/A
- P/E Ratio
- RMCO N/A
- NXTC N/A
- Revenue Growth
- RMCO 292.46
- NXTC N/A
- 52 Week Low
- RMCO $0.76
- NXTC $2.69
- 52 Week High
- RMCO $1.88
- NXTC $20.16
- Technical
- Relative Strength Index (RSI)
- RMCO 66.56
- NXTC 42.50
- Support Level
- RMCO $1.28
- NXTC $4.75
- Resistance Level
- RMCO $1.53
- NXTC $5.42
- Average True Range (ATR)
- RMCO 0.11
- NXTC 0.43
- MACD
- RMCO 0.02
- NXTC -0.01
- Stochastic Oscillator
- RMCO 96.58
- NXTC 2.99
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.